Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Heparin AnticoaguLation to Improve Outcomes in Septic Shock: The HALO International Phase II RCT

NCT03378466 is registered in ClinicalTrials.gov with University of Manitoba as lead sponsor.

NCT NCT03378466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03378466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Heparin AnticoaguLation to Improve Outcomes in Septic Shock: The HALO International Phase II RCT
Lead sponsor
University of Manitoba
Phase
Phase 2
Overall status
Terminated
Start date
March 12, 2018
Completion date
December 31, 2021
Enrollment
178 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock, vasodilatory shock